Although prostate cancers initially respond favorably to androgen deprivation, regrowth of androgen-independent tumors is very common. The molecular mechanisms involved in the regression and regrowth of prostate cancers are unknown. We applied complementary DNA microarrays containing 6,605 genes to identify gene expression changes in the CWR22 human prostate cancer xenograft model system 12 h to 16 d after androgen deprivation, as well as in recurrent androgen-independent CWR22R tumors. We identified 59 genes whose expression levels decreased threefold in response to castration, including several cell cycle regulators. In the recurrent tumors, expression levels of 57 of these genes (96.6%) were restored, suggesting reactivation of androgen signaling in the absence of ligand. Of the 6,605 genes, 251 (3.8%) were differentially expressed between primary and recurrent prostate cancers. These genes included those coding for transcription factors, signal transducers, growth and survival factor receptors and cell cycle regulators. One of the most overexpressed genes in the recurrent tumors was S100P, which encodes a calcium-binding signaling protein. The role of S100P in the progression of prostate cancers in vivo was further suggested by in situ hybridization of messenger RNA and protein immunostaining of 440 clinical tumor specimens in a tissue microarray format. Tissue microarray analysis indicated that S100P expression increased significantly (P<0.0001) during the progression of prostate cancers in vivo, with the highest levels seen in hormonerefractory and metastatic prostate cancers. The cDNA microarray data may also suggest targets for therapeutic intervention. For example, several direct and indirect rapamycin targets were differentially expressed in recurrent tumors. Rapamycin also inhibited CWR22R prostate cancer cell growth in vitro. Tissue and cDNA microarrays enable rapid identification, prioritization and validation of gene targets that may have diagnostic and therapeutic significance in the management of patients with hormone-refractory human prostate cancer. Hormoneindependent prostate cancer growth seems to require re-expression of androgendependent signaling pathways as well as altered expression of several other genes.
Breast cancer metastasis can be predicted by morphometric quantification of mitotic activity in the tumor perimeter according to the Mitotic Activity Index (MAI). We used Affymetrix HuFL GeneChips to compare approximately 6,000 RNAs from 12 high-MAI (10 mitoses per 10 h.p.f., high metastatic risk) and 11 low-MAI, premenopausal, lymph-node-negative, primary breast cancers. We identified 51 discriminating genes as having t-statistics above the randomly permuted data set background (Permax 0.96) and means differing by 100 expression units, and a twofold ratio. The largest category consisted of cell cycle and division genes, usually (12/13) those with the highest levels of expression in high-MAI tumors. Internal validation of the list was provided by the following: one gene independently selected by two probe sets during analysis; five pairs of genes known to be co-expressed and one instance of reciprocal regulation of ligand and receptor. Genes that may contribute to divergent aggressiveness between groups include seven membraneassociated genes participating in cell-cell interactions, five extracellular matrix genes, and five genes encoding matrix-modifying proteolytic enzymes. A graphical classification model was tested using a 10% jackknife and 50 genes selected in each cycle. The mean level of expression in the low-MAI group and the difference of means between the groups were rank-ordered. These two variables were plotted on a triangular coordinate system against actual expression values for each tumor. Distinctive bimodally shifting cloud patterns of data points were used to assign 78% (18/23) of jackknifed tumors to their correct MAI groups. Expression profiling can be used to discover genes associated with breast cancer metastasis, and these may be of practical use in prospective risk classification.
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